Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,148.42
(
0.00%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 10/03/2012 8:31:30 PM

Wednesday, October 03, 2012 8:31:30 PM

Post# of 257580
XOMA/Servier modify uveitis program by converting the EYEGUARD-C study from a simple safety study to a safety-and-efficacy study in patients with stable disease.

CC slides on the EYEGUARD-A, -B, and –C studies:
http://investors.xoma.com/common/download/download.cfm?companyid=XOMA&fileid=603353&filekey=5878d809-0e87-4e62-822c-3dc730ad0260&filename=10_03_12_EYEGUARD_Slides_Final.pdf

Press release:
http://finance.yahoo.com/news/xoma-initiates-safety-efficacy-study-200000899.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today